Kevin Zorzi

Nice, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial.

The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial.

Journal: EClinicalMedicine

Published: July 30, 2025

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.

Artificial intelligence-based personalised rituximab treatment protocol in membranous nephropathy (iRITUX): protocol for a multicentre randomised control trial.

Journal: BMJ open

Published: April 03, 2025

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy.

Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy.

Journal: Kidney international reports

Published: March 01, 2025

Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy.

Artificial intelligence to guide rituximab therapy in patients with phospholipase A2 receptor-associated membranous nephropathy.

Journal: Clinical kidney journal

Published: November 16, 2024

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.

Obinutuzumab and Ofatumumab are More Effective Than Rituximab in the Treatment of Membranous Nephropathy Patients With Anti-Rituximab Antibodies.

Journal: Kidney international reports

Published: October 02, 2024

Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence.

Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence.

Journal: Kidney international reports

Published: June 29, 2023

Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.

Both Humoral and Cellular Immune Responses to SARS-CoV-2 Are Essential to Prevent Infection: a Prospective Study in a Working Vaccinated Population from Southern France.

Journal: Journal of clinical immunology

Published: January 20, 2023

Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease.

Humoral and cellular responses after a third dose of SARS-CoV-2 mRNA vaccine in patients with glomerular disease.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: July 19, 2022

Low baseline IFN-γ response could predict hospitalization in COVID-19 patients.

Low baseline IFN-γ response could predict hospitalization in COVID-19 patients.

Journal: Frontiers in immunology

Published: May 26, 2022

Air pollution exposure induces a decrease in type II interferon response: A paired cohort study.

Air pollution exposure induces a decrease in type II interferon response: A paired cohort study.

Journal: EBioMedicine

Published: May 10, 2022

Toxic Occupational Exposures and Membranous Nephropathy.

Toxic Occupational Exposures and Membranous Nephropathy.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: March 09, 2022

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.

Journal: Frontiers in immunology

Published: July 09, 2021

Showing 1-12 of 24

Last Updated: 09/26/2026